Search Results - Louis P Garrison

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting? by Bernarda Zamora, Louis P. Garrison, Aig Unuigbe, Adrian Towse

    Published in Cost Effectiveness and Resource Allocation (2021-03-01)
    Get full text
    Article


  2. 2

    Why is the market design for innovative pharmaceuticals not well understood? by Francisco Olivenca, Jose Diaz, Sreeram V Ramagopalan, Louis P Garrison Jr

    Article


  3. 3

    Is the price right? Paying for value today to get more value tomorrow by Sreeram V. Ramagopalan, Jose Diaz, Grace Mitchell, Louis P. Garrison, Peter Kolchinsky

    Published in BMC Medicine (2024-01-01)
    Get full text
    Article


  4. 4

    The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. by Bruce Wang, Joshua A Roth, Hiep Nguyen, Eugene Felber, Wes Furnback, Louis P Garrison

    Published in PLoS ONE (2015-01-01)
    Get full text
    Article


  5. 5

    A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone app. by Fredrick Chite Asirwa, Brian W Bresnahan, Faith Yego, Dana Duncan, James K Karichu, Louis P Garrison

    Published in PLoS ONE (2025-01-01)
    Get full text
    Article


  6. 6

    Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications by András Incze, András Incze, Zoltán Kaló, Zoltán Kaló, Jaime Espín, Éva Kiss, Sophia Kessabi, Louis P. Garrison

    Published in Frontiers in Pharmacology (2022-04-01)
    Get full text
    Article


  7. 7

    Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison by Louis P Garrison, Joseph B Babigumira, Samantha Clark, Saeed S Hamid, James K Karichu, Mindy M Cheng, Maciej B Maniecki

    Published in BMJ Open (2023-05-01)
    Get full text
    Article


  8. 8

    Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. by Joseph B Babigumira, Barbara Castelnuovo, Andy Stergachis, Agnes Kiragga, Petra Shaefer, Mohammed Lamorde, Andrew Kambugu, Alice Muwanga, Louis P Garrison

    Published in PLoS ONE (2011-03-01)
    Get full text
    Article


  9. 9

    Val (EU) xit: do we need an international ISPOR value flower? by Sreeram V Ramagopalan, Manuel Gomes, Isabelle Durand-Zaleski, Bill Malcolm, Jose Diaz, Grace Mitchell, Jonathan Pearson-Stuttard, Louis P Garrison Jr

    Article


  10. 10

    New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement by Philip O. Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Stuart Carroll, Bernhard Ultsch, Kavisha Jayasundara, Mathieu Uhart, Louis P. Garrison, Jr.

    Published in Vaccines (2024-02-01)
    Get full text
    Article


  11. 11

    Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States by Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston

    Published in Neurology and Therapy (2024-09-01)
    Get full text
    Article


  12. 12

    Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective by Phil McEwan, Paolo Antonio Ascierto, Kevin Harrington, Michael B Atkins, Casey Quinn, Louis P Garrison, Anja K Pownell, Gérard de Pouvourville, Samuel Wagner, John Borrill, Elise Wu

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


  13. 13

    Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. by Elisabeth L Vodicka, Michael H Chung, Marita R Zimmermann, Rose J Kosgei, Fan Lee, Nelly R Mugo, Timothy C Okech, Samah R Sakr, Andy Stergachis, Louis P Garrison, Joseph B Babigumira

    Published in PLoS ONE (2019-01-01)
    Get full text
    Article


  14. 14

    Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda by Meng Li, Agnes Nyabigambo, Patricia Navvuga, Elly Nuwamanya, Afra Nuwasiima, Paschal Kaganda, Francis T. Asiimwe, Elisabeth Vodicka, Noleb M. Mugisha, Aggrey Mukose, Doris K. Kwesiga, Solomon J. Lubinga, Louis P. Garrison, Jr, Joseph B. Babigumira

    Published in Papillomavirus Research (2017-12-01)
    Get full text
    Article


  15. 15

    Capturing the Value of Vaccination within Health Technology Assessment and Health Economics—Practical Considerations for Expanding Valuation by Including Key Concepts by Eliana Biundo, Mariia Dronova, Annie Chicoye, Richard Cookson, Nancy Devlin, T. Mark Doherty, Stephanie Garcia, Antonio J. Garcia-Ruiz, Louis P. Garrison, Terry Nolan, Maarten Postma, David Salisbury, Hiral Shah, Shazia Sheikh, Richard Smith, Mondher Toumi, Jurgen Wasem, Ekkehard Beck

    Published in Vaccines (2024-07-01)
    Get full text
    Article


  16. 16

    The evolving value assessment of cancer therapies: Results from a modified Delphi study by Myrto Lee, Hugo Larose, Martin Gräbeldinger, Jon Williams, Anne-Marie Baird, Susan Brown, Johannes Bruns, Russell Clark, Javier Cortes, Giuseppe Curigliano, Andrea Ferris, Louis P. Garrison, Y.K. Gupta, Ravindran Kanesvaran, Gary Lyman, Luca Pani, Zack Pemberton-Whiteley, Tomas Salmonson, Peter Sawicki, Barry Stein, Dong-Churl Suh, Galina Velikova, Jens Grueger

    Published in Health Policy Open (2024-12-01)
    Get full text
    Article


Search Tools: